|
- Bausch + Lomb Official Home Page
Bausch + Lomb is one of the world's largest suppliers of contact lenses, lens care products, prescription pharmaceuticals, intraocular lenses and other eye surgery products
- Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista . . .
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses | Bausch + Lomb CorporationTASS, a potential complication in any cataract surgery, is an inflammatory reaction inside the eye that can have a variety of causes When it occurs, this complication typically appears 12 – 48 hours after eye surgery All enVista TASS
- Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United . . .
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States | Bausch + Lomb CorporationEngineered for precision and speed, Arise uses advanced algorithms to instantly interpret corneal topography images and recommend lens designs in seconds – no fitting set required It is designed for lens fitters of all experience levels and efficiently evaluates lens centration and
- Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap . . .
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences | Bausch + Lomb CorporationGlaucoma is a chronic, progressive neurodegenerative disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve As one of the leading causes of preventable blindness, glaucoma affects about four million people in the United States, but if caught early, it
- Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and . . .
VAUGHAN, Ontario -- (BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2023 financial results
- Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results . . .
Revenue of $1 280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results
- Bausch + Lomb Acquires AcuFocus, Inc. - Lomb Corporation
Bausch + Lomb Acquires AcuFocus, Inc | Bausch + Lomb CorporationAcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care, including the IC-8 ® Apthera ™ intraocular lens (IOL), which was approved by the U S Food and Drug Administration in July 2022 as the first and only small aperture non-toric extended depth of focus (EDOF
- About Our Company: Bausch + Lomb
By listening to feedback from customers, patients and consumers and using data-driven insights, we develop modernized vision care, consumer health care, surgical and pharmaceutical products to help millions of people worldwide see better to live better
|
|
|